Health

Clinical Trial Updates: Cancer Trial Funding, Multiple Myeloma MRD Milestone & PTSD Study Enrollment

Clinical research continues to progress through strategic financing, evolving clinical endpoints, and innovative device-based therapies. Recent developments include new funding for an oncology program, growing recognition of measurable residual disease (MRD) as a key endpoint in multiple myeloma, and first-patient enrollment in a PTSD study evaluating non-invasive neuromodulation.

Recent coverage from Clinical Trial Vanguard highlights how these milestones are shaping the future of clinical development.

Incyclix Bio Secures New $5M for Cancer Trial Development

Incyclix Bio has secured an additional $5 million extension to its Series B financing to support development of INX-315, a selective CDK2 inhibitor currently advancing in oncology studies. The added capital is expected to help accelerate clinical progress and expand the company’s precision cancer therapy pipeline.

Financing rounds remain a critical driver for early-stage biotech companies, particularly when supporting first-in-class or highly targeted cancer programs.

Learn more in Incyclix Bio’s Promising Cancer Trial Gets New $5M Fund.

MRD Gains Importance as a Clinical Endpoint in Multiple Myeloma

Clinical trial endpoints continue to evolve beyond traditional survival metrics. New analysis of the EMN24 IsKia Phase 3 trial suggests that measurable residual disease (MRD) may now be one of the most meaningful indicators of treatment effectiveness in newly diagnosed multiple myeloma.

MRD-based assessment may help speed future trial readouts, improve treatment personalization, and strengthen regulatory decision-making in hematologic oncology.

Further insights are available in MRD Is Now the Endpoint That Matters: The EMN24 IsKia Trial Just Proved It.

gammaCore nVNS PTSD Study Enrolls First Patient

Innovation in mental health research is also advancing. A new clinical study evaluating gammaCore non-invasive vagus nerve stimulation (nVNS) for post-traumatic stress disorder (PTSD) has enrolled its first patient. Device-based therapies such as nVNS are drawing attention as potential non-pharmacologic options for psychiatric and neurological disorders.

First-patient enrollment marks an important milestone in determining whether neuromodulation can offer meaningful benefit in PTSD management.

Read more in Pioneering gammaCore nVNS Study for PTSD Enrolls First Patient.

Key Trends Across Current Clinical Research

These developments highlight several broader trends shaping modern clinical trials:

  • Continued investor support for precision oncology pipelines
  • Rising use of MRD as a surrogate endpointin hematologic cancers
  • Expansion of non-invasive device therapiesin mental health care

Tracking these milestones helps researchers, clinicians, and industry stakeholders understand how innovation continues progressing across oncology, neuroscience, and trial methodology.

Related Articles

Back to top button